Non-Small-Cell Lung Cancer Market Size Set for Rapid Expansion, Valued at USD 36.9 billion by 2031 | CAGR of 9.3%

The non-small cell lung cancer market grow at a CAGR of around 9.3% from 2021-2031.

PORTLAND, OR, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- Allied Market Research published a report, titled, "Global Non-Small-Cell Lung Cancer Market by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others), by Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), by Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031". According to the report, the global non-small cell lung cancer industry generated $15.3 billion in 2021 and is anticipated to generate $36.9 billion by 2031, witnessing a CAGR of 9.3% from 2022 to 2031.

Non-small cell lung cancer is caused when the cells present in the body grow at an uncontrolled rate, leading to the formation of a tumor. NSCLC has different stages based on its progression. STAGE IV is the final stage of the disease, which is marked by the spreading of tumors into others parts of body. The management of NSCLC in patients requires the use of different treatments, such as immunotherapy, targeted therapy, and chemotherapy.

The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐆𝐫𝐚𝐩𝐡𝐬 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬 𝐇𝐞𝐫𝐞: https://www.alliedmarketresearch.com/request-sample/666

𝐑𝐢𝐬𝐞 𝐢𝐧 𝐩𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞 𝐨𝐟 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐨𝐜𝐜𝐮𝐫 𝐢𝐧 𝐩𝐞𝐨𝐩𝐥𝐞 𝐰𝐡𝐨 𝐬𝐦𝐨𝐤𝐞 𝐚𝐧𝐝 𝐜𝐨𝐧𝐬𝐮𝐦𝐞 𝐭𝐨𝐛𝐚𝐜𝐜𝐨 𝐝𝐫𝐢𝐯𝐞 𝐭𝐡𝐞 𝐠𝐫𝐨𝐰𝐭𝐡 𝐨𝐟 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐧𝐨𝐧 𝐬𝐦𝐚𝐥𝐥 𝐜𝐞𝐥𝐥 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐚𝐫𝐤𝐞𝐭. 𝐇𝐨𝐰𝐞𝐯𝐞𝐫, 𝐡𝐢𝐠𝐡-𝐜𝐨𝐬𝐭 𝐞𝐱𝐩𝐞𝐧𝐝𝐢𝐭𝐮𝐫𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐧𝐨𝐧-𝐬𝐦𝐚𝐥𝐥 𝐜𝐞𝐥𝐥 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐚𝐧𝐝 𝐬𝐭𝐫𝐢𝐧𝐠𝐞𝐧𝐭 𝐠𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐫𝐮𝐥𝐞𝐬 𝐟𝐨𝐫 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐫𝐞𝐬𝐭𝐫𝐢𝐜𝐭 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐫𝐨𝐰𝐭𝐡. 𝐌𝐨𝐫𝐞𝐨𝐯𝐞𝐫, 𝐰𝐢𝐝𝐞𝐬𝐩𝐫𝐞𝐚𝐝 𝐮𝐬𝐞 𝐨𝐟 𝐬𝐧𝐞𝐚𝐤𝐞𝐫𝐬 𝐢𝐧 𝐧𝐮𝐦𝐞𝐫𝐨𝐮𝐬 𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭𝐬 𝐚𝐧𝐝 𝐚 𝐥𝐚𝐫𝐠𝐞 𝐜𝐨𝐧𝐬𝐮𝐦𝐞𝐫 𝐛𝐚𝐬𝐞 𝐢𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐟𝐢𝐭𝐧𝐞𝐬𝐬 & 𝐠𝐲𝐦 𝐯𝐢𝐬𝐢𝐭𝐨𝐫𝐬, 𝐚𝐭𝐡𝐥𝐞𝐭𝐞𝐬, 𝐚𝐧𝐝 𝐫𝐨𝐜𝐤 𝐜𝐥𝐢𝐦𝐛𝐞𝐫𝐬, 𝐩𝐫𝐞𝐬𝐞𝐧𝐭 𝐧𝐞𝐰 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐢𝐧𝐠 𝐲𝐞𝐚𝐫𝐬.

𝐓𝐨𝐩 𝐍𝐨𝐧-𝐒𝐦𝐚𝐥𝐥 𝐂𝐞𝐥𝐥 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬

• F. Hoffmann-La Roche Ltd,
• Novartis AG,
• Pfizer Inc.,
• Astrazeneca,
• Eli Lilly and Company,
• Merck & Co., Inc.,
• Bristol-Myers Squibb Company,
• Celgene Corporation,
• Sanofi,
• Boehringer Ingelheim

𝐍𝐨𝐧-𝐒𝐦𝐚𝐥𝐥 𝐂𝐞𝐥𝐥 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐜𝐚𝐧 𝐛𝐞 𝐝𝐨𝐧𝐞 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐬𝐞𝐯𝐞𝐫𝐚𝐥 𝐟𝐚𝐜𝐭𝐨𝐫𝐬, 𝐢𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠:

Based on type, the adenocarcinoma segment held the highest market share in 2021, accounting for nearly half of the global non small cell lung cancer market, and is estimated to maintain its leadership status throughout the forecast period, owing to rise in smoking on regular basis around the globe. However, the large cell carcinoma segment is projected to manifest the highest CAGR of 11.3% from 2022 to 2031, owing to the advancements in R&D activities.

Based on treatment type, the targeted therapy segment held the highest market share in 2021, accounting for more than half of the global non small cell lung cancer market, and is estimated to maintain its leadership status throughout the forecast period, owing to its potential to prevent the growth of malignant cells. However, the immunotherapy segment is projected to manifest the highest CAGR of 12.7% from 2022 to 2031, owing to constant investment in developing new products by the key players.

Based on distribution channel, the hospital pharmacy segment accounted for the largest share in 2021, contributing to more than two-thirds of the global non small cell lung cancer market, and is projected to maintain its lead position during the forecast period. This is owing to prevalence of non-small cell lung cancer diseases, such as adenocarcinoma and large cell carcinoma and increase in number of hospitalization of patients suffering with NSCLC. However, the online pharmacy segment is expected to portray the largest CAGR of 15.1% from 2022 to 2031, owing to constant focus of market players to establish their products on e-commerce sales channels along with increase in number of online platforms related to healthcare.

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for around two-fifths of the global non small cell lung cancer market, and is likely to dominate the market during the forecast period, owing to the presence of key players, rising government initiatives, well-developed healthcare infrastructure, and rising awareness about the innovations in healthcare sector. However, the Asia-Pacific region is expected to witness the fastest CAGR of 10.5% from 2022 to 2031, owing to the investments by the public and private market players in this field.

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/666

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+ 1800-792-5285
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube
X